Janux impresses again
The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.
A combination Revolution
Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.
FDA red and green lights: November 2024
Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.
ASH 2024 preview – best of the rest
Myelofibrosis projects and Merck's ROR1 ADC fight for attention at this month's conference.
The month ahead: December’s upcoming events
Party season approaches; but first, conferences.
Biohaven aims to become an oncology fast follower
The group’s cancer focus is a TROP2 ADC it reckons could have a safety and efficacy edge.
